相关实验视频

Updated: Jul 12, 2025

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

囊性纤维化中肠道功能障碍的量化:个体间和个体内可变性

Laura A Duckworth¹, Kimberly A Sutton¹, Nurmohammad Shaikh¹

¹Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Washington University in St Louis, St Louis, MO.

The Journal of pediatrics

|October 22, 2023

概括

像便中利波卡林-2 (fLcn2) 这样的生物标志物在囊性纤维化 (CF) 肠道功能障碍中升高,可以预测肺功能下降. 需要进一步的研究来确认FLcn2的存在.

科学领域:

胃肠病学胃肠病学
肺部病理学肺部病理学
生物标志物发现发现

背景情况:

囊性纤维化 (CF) 与胃肠功能障碍有关.
在CF中确定肠道功能障碍的可靠生物标志物对于患者管理至关重要.
现有的生物标志物需要验证其可重复性和与临床结果的相关性.

研究的目的:

评估小儿囊性纤维化 (CF) 患者肠道功能障碍的生物标志物.
评估这些生物标志物在短时间间隔 (2周至3个月) 的可重复性.
确定生物标志物的个体间变化是否与CF的临床结果相关.

主要方法:

一项涉及1至21岁CF儿童的横截面,有限的纵向研究.
对血液和便样本进行肠道炎症标志物 (便calprotectin [fCal],脂素-2 [fLcn2],新素) 和透性的分析.
使用了酶免疫试验,对照样本来自没有CF的儿童.

主要成果:

便中的calprotectin (fCal),lipocalin-2 (fLcn2) 和neopterin在CF患者中明显高于对照组.
fCal与体重对年龄z-score,BMIz-score和1秒内强制呼气体积 (FEV1) 的变化存在负相关性.
fLcn2与FEV1有负相关性,这表明与肺功能下降有联系.

结论:

便中的脂素-2 (fLcn2) 在患有CF的个体中升高,可以作为恶化肺功能的预测因素.
建议进行进一步的研究,以探索fLcn2与CF的其他临床结果之间的相关性.
观察到LPS抗体的个体内稳定性,但其他标记物显示出变化.

关键词:

便中的calprotectin是一种便的calprotectin.在便中使用Lipocalin-2 便中的新蛋白.肠道炎症是一种肠道炎症.肠道的通透性肠道的通透性血脂多糖抗体的抗体是血中的脂多糖.血脂多聚糖结合蛋白质是血中的结合蛋白质.

更多相关视频

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

相关概念视频

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...